Unaudited Condensed Consolidated Financial Statements and Management's Plans	9 Months Ended
Sep. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Unaudited Condensed Consolidated Financial Statements and Management's Plans	(1) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND MANAGEMENT’S PLANS Zynex, Inc. (a Nevada corporation) has its headquarters in Lone Tree, Colorado. The Company operates in one primary business segment, Electrotherapy and Pain Management Products. As of September 30, 2015, the Company has three active subsidiaries, Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation), Zynex Monitoring Solutions Inc. (“ZMS,” a wholly-owned Colorado corporation) and Zynex Europe, ApS (“ZEU,” a wholly-owned Denmark corporation). In June 2015, the Company had incorporated Pharmazy, Inc. (“Pharmazy”) as a wholly-owned subsidiary of ZMI to conduct the Company’s compound pharmacy operations previously conducted by ZMI, but through the date of the filing of this Form 10-Q, ZMI had not transferred any of the compound pharmacy assets to Pharmazy. The Company’s compound pharmacy operations continue as a division of ZMI dba Pharmazy. Beginning in April 2015, the Company stopped offering billing and consulting services to customers through its now inactive subsidiary Zynex Billing and Consulting, LLC (“ZBC,” an 80% owned Colorado limited liability company). In addition, the Company previously operated through a now inactive subsidiary Zynex NeuroDiagnostics, Inc. (“ZND,” a wholly owned Colorado corporation). Neither ZEU, ZMS nor Pharmazy have generated significant revenues at this point. The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries. The unaudited condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Amounts as of December 31, 2014, are derived from those audited consolidated financial statements. These interim condensed consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which has previously been filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of September 30, 2015 and the results of its operations and its cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2015, are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year. (1) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND MANAGEMENT’S PLANS (continued) The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the nine months ended September 30, 2015, the Company reported a net loss of $1,711 and for the years ended December 31, 2014 and 2013, the Company reported net losses of $6,199 and $7,301, respectively. Further, as of September 30, 2015 the Company had no available borrowing under its line of credit although, based on an interim agreement with the bank, the lender continues to make additional loans to the Company based on the Company’s cash collections. Furthermore, the Company’s working capital deficit of $(2,352) at December 31, 2014, had increased to a working capital deficit of $(3,674) at September 30, 2015. These losses, limited liquidity and increasing working capital deficit raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company developed its operating plans for 2015 to emphasize revenue growth and cash flow. In 2015, management planned to focus its attention on increasing the number of sales representatives, promoting its EZ Prescription order program and continued improvements to its billing organization and processes. Net revenues are comprised of sales and rental billings, reduced by estimated insurance company or governmental agency (collectively “Third-party Payors”) reimbursement deductions and a reserve / allowance for uncollectible accounts. Total net revenue for the nine months ended September 30, 2015, was $8,923 compared to $8,921 for the nine months ended September 30, 2014. The Company has significantly reduced costs of operations year over year to a level that more appropriate with revenue and cash collections. The Company has and will continue to monitor and control costs going forward. If the Company continues to control costs and increases its revenue, the Company may return to profitability in future years. There can be no assurance that the Company will be able to increase revenue and profitability. In addition, the Company must address with its liquidity issues and bank financing; of which there can be no assurance that the Company will be able to do so. The Company believes that as a result of the restructuring activities over the past two years, the Company’s cash flows from operating activities will be sufficient to fund the Company’s cash requirements through the next twelve months. However, there is no guarantee that the Company will be able to meet the requirements of its 2015 financial plan. The Company is not in compliance with the financial covenants under the terms of its line of credit with Triumph Healthcare Finance (the “Lender”). In July 2014, the Lender notified the Company that it would no longer make additional loans under the credit agreement and that it was exercising its default remedies under the credit agreement, including, among others, accelerating the repayment of all outstanding obligations under the credit agreement and collecting the Company’s bank deposits to apply towards the outstanding obligations. The Lender agreed to forbear from the exercise of its rights and remedies under the terms of the credit agreement through December 31, 2015 and continues to make additional loans to the Company based on the Company’s cash collections. As of November 13, 2015, the Company had $4,261 of outstanding borrowings under the credit agreement. The Company and the Lender continue to negotiate the terms of an accelerated repayment of the amounts outstanding under the credit agreement and continued extension of the forbearance agreement. However, no assurance can be given that the Lender will continue to make such additional loans, or that the parties will agree on a repayment plan acceptable to the Company. The Company’s business plan for the balance of 2015 and 2016 focuses on the Company’s effort to accomplish organic growth in revenues and cash flow, through increasing the number of sales representatives, using its EZ Prescription order program and continued improvements to its billing organization and processes. The Company’s long-term business plan contemplates organic growth in revenues through the addition of new products such as the ZMS Blood Volume Monitor that could contribute additional revenue for the Company. Management believes that its cash flow projections for the remainder of 2015 are achievable and that sufficient cash will be generated to meet the Company’s currently restrained operating requirements for the remainder of 2015, assuming that the Lender continues to make additional loans and the vendors continue to work with Company on the slow payment of past due bills. However, there is no guarantee that the Company will be able to meet the requirements of its 2015 cash flow projection or will be able to address its working capital shortages which increased during the nine months ended September 30, 2015 (a negative $3.7 million) as compared to December 31, 2014 (a negative $2.4 million). A principal component of our negative working capital is our line of credit and past due accounts payable which are considered a current liability in their entirety. The Company is actively seeking external financing through the issuance of debt or sale of equity, and the Company is not certain whether any such financing would be available to the Company on acceptable terms, or at all. The net losses and negative working capital may make it difficult to raise any new capital. In addition, any additional debt would require the approval of the Lender. The Company’s dependence on operating cash flow means that risks involved in the Company’s business can significantly affect the Company’s liquidity. Contingencies such as unanticipated shortfalls in revenues or increases in expenses could affect the Company’s projected revenues, cash flows from operations and liquidity, which may force the Company to curtail its operating plan or impede the Company’s ability to grow.

(1) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND MANAGEMENT’S PLANS

Zynex, Inc. (a Nevada corporation) has its headquarters in Lone Tree, Colorado. The Company operates in one primary business segment, Electrotherapy and Pain Management Products. As of September 30, 2015, the Company has three active subsidiaries, Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation), Zynex Monitoring Solutions Inc. (“ZMS,” a wholly-owned Colorado corporation) and Zynex Europe, ApS (“ZEU,” a wholly-owned Denmark corporation). In June 2015, the Company had incorporated Pharmazy, Inc. (“Pharmazy”) as a wholly-owned subsidiary of ZMI to conduct the Company’s compound pharmacy operations previously conducted by ZMI, but through the date of the filing of this Form 10-Q, ZMI had not transferred any of the compound pharmacy assets to Pharmazy. The Company’s compound pharmacy operations continue as a division of ZMI dba Pharmazy.

Beginning in April 2015, the Company stopped offering billing and consulting services to customers through its now inactive subsidiary Zynex Billing and Consulting, LLC (“ZBC,” an 80% owned Colorado limited liability company). In addition, the Company previously operated through a now inactive subsidiary Zynex NeuroDiagnostics, Inc. (“ZND,” a wholly owned Colorado corporation). Neither ZEU, ZMS nor Pharmazy have generated significant revenues at this point. The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.

The unaudited condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Amounts as of December 31, 2014, are derived from those audited consolidated financial statements. These interim condensed consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which has previously been filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of September 30, 2015 and the results of its operations and its cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2015, are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

(1) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND MANAGEMENT’S PLANS (continued)

The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the nine months ended September 30, 2015, the Company reported a net loss of $1,711 and for the years ended December 31, 2014 and 2013, the Company reported net losses of $6,199 and $7,301, respectively. Further, as of September 30, 2015 the Company had no available borrowing under its line of credit although, based on an interim agreement with the bank, the lender continues to make additional loans to the Company based on the Company’s cash collections. Furthermore, the Company’s working capital deficit of $(2,352) at December 31, 2014, had increased to a working capital deficit of $(3,674) at September 30, 2015. These losses, limited liquidity and increasing working capital deficit raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company developed its operating plans for 2015 to emphasize revenue growth and cash flow. In 2015, management planned to focus its attention on increasing the number of sales representatives, promoting its EZ Prescription order program and continued improvements to its billing organization and processes. Net revenues are comprised of sales and rental billings, reduced by estimated insurance company or governmental agency (collectively “Third-party Payors”) reimbursement deductions and a reserve / allowance for uncollectible accounts. Total net revenue for the nine months ended September 30, 2015, was $8,923 compared to $8,921 for the nine months ended September 30, 2014. The Company has significantly reduced costs of operations year over year to a level that more appropriate with revenue and cash collections. The Company has and will continue to monitor and control costs going forward. If the Company continues to control costs and increases its revenue, the Company may return to profitability in future years. There can be no assurance that the Company will be able to increase revenue and profitability. In addition, the Company must address with its liquidity issues and bank financing; of which there can be no assurance that the Company will be able to do so.

The Company believes that as a result of the restructuring activities over the past two years, the Company’s cash flows from operating activities will be sufficient to fund the Company’s cash requirements through the next twelve months. However, there is no guarantee that the Company will be able to meet the requirements of its 2015 financial plan. The Company is not in compliance with the financial covenants under the terms of its line of credit with Triumph Healthcare Finance (the “Lender”). In July 2014, the Lender notified the Company that it would no longer make additional loans under the credit agreement and that it was exercising its default remedies under the credit agreement, including, among others, accelerating the repayment of all outstanding obligations under the credit agreement and collecting the Company’s bank deposits to apply towards the outstanding obligations. The Lender agreed to forbear from the exercise of its rights and remedies under the terms of the credit agreement through December 31, 2015 and continues to make additional loans to the Company based on the Company’s cash collections. As of November 13, 2015, the Company had $4,261 of outstanding borrowings under the credit agreement. The Company and the Lender continue to negotiate the terms of an accelerated repayment of the amounts outstanding under the credit agreement and continued extension of the forbearance agreement. However, no assurance can be given that the Lender will continue to make such additional loans, or that the parties will agree on a repayment plan acceptable to the Company.

The Company’s business plan for the balance of 2015 and 2016 focuses on the Company’s effort to accomplish organic growth in revenues and cash flow, through increasing the number of sales representatives, using its EZ Prescription order program and continued improvements to its billing organization and processes. The Company’s long-term business plan contemplates organic growth in revenues through the addition of new products such as the ZMS Blood Volume Monitor that could contribute additional revenue for the Company. Management believes that its cash flow projections for the remainder of 2015 are achievable and that sufficient cash will be generated to meet the Company’s currently restrained operating requirements for the remainder of 2015, assuming that the Lender continues to make additional loans and the vendors continue to work with Company on the slow payment of past due bills. However, there is no guarantee that the Company will be able to meet the requirements of its 2015 cash flow projection or will be able to address its working capital shortages which increased during the nine months ended September 30, 2015 (a negative $3.7 million) as compared to December 31, 2014 (a negative $2.4 million). A principal component of our negative working capital is our line of credit and past due accounts payable which are considered a current liability in their entirety.

The Company is actively seeking external financing through the issuance of debt or sale of equity, and the Company is not certain whether any such financing would be available to the Company on acceptable terms, or at all. The net losses and negative working capital may make it difficult to raise any new capital. In addition, any additional debt would require the approval of the Lender. The Company’s dependence on operating cash flow means that risks involved in the Company’s business can significantly affect the Company’s liquidity. Contingencies such as unanticipated shortfalls in revenues or increases in expenses could affect the Company’s projected revenues, cash flows from operations and liquidity, which may force the Company to curtail its operating plan or impede the Company’s ability to grow.